Stocktoria
TANDEM DIABETES CARE INC TNDM
TANDEM DIABETES CARE INC (TNDM) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.0B at a -20.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.12 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.426 |
| Retained earnings / assets | -1.422 |
| EBIT / assets | -0.213 |
| Equity / liabilities | 0.214 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TNDM | TANDEM DIABETES CARE INC | 3/9 | -3.04 | — | +7.9% |
| EMBC | Embecta Corp. | 6/9 | 1.99 | 2.2 | -3.8% |
| INSP | Inspire Medical Systems, Inc. | 6/9 | 9.88 | 9.1 | +13.6% |
| OFIX | Orthofix Medical Inc. | 5/9 | 1.02 | — | +2.9% |
| ATEC | Alphatec Holdings, Inc. | 6/9 | -4.63 | — | +25% |
| IRTC | iRhythm Holdings, Inc. | 5/9 | 0.78 | — | +26.2% |
| HAE | HAEMONETICS CORP | 7/9 | 2.85 | 36.1 | -2% |
About TANDEM DIABETES CARE INC
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
FAQ
Is TNDM financially healthy?
TANDEM DIABETES CARE INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TNDM pay a dividend?
No, TANDEM DIABETES CARE INC does not currently pay a dividend.
How profitable is TNDM?
In FY2025, TANDEM DIABETES CARE INC had a net margin of -20.2% and a return on equity of -131.9%.
What is the analyst price target for TNDM?
The average Wall-Street price target for TANDEM DIABETES CARE INC is $28.88, about 23.2% above the recent price, from 20 analysts (consensus: buy).
Is TNDM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TANDEM DIABETES CARE INC: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.